Tonix Pharmaceuticals shares rise 4.89% in premarket after FDA approval target for TNX-102 SL and improved Q2 earnings.

Tonix Pharmaceuticals Holding Corp. surged 4.89% in premarket trading, driven by the FDA's PDUFA target date for its lead drug TNX-102 SL, which is set for August 15, 2025, and the company's second-quarter financial report showing a significant narrowing of net loss, with earnings per share of -$3.86, beating analyst expectations of -$10.73. Additionally, the company was added to the Russell 3000® and Russell 2000® indices in June 2025, increasing market attention and potential capital inflows.